Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Synchrony Financial (SYF) vs Vir Biotechnology Inc. Common Stock (VIR) Price & Performance

Synchrony FinancialTrade
Vir Biotechnology Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Synchrony Financial vs Vir Biotechnology Inc. Common Stock — how do they compare? Synchrony Financial trades at $71.41 (market cap $23.94B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Synchrony Financial is far larger — about 13.3× Vir Biotechnology Inc. Common Stock's market cap, and Synchrony Financial pays a 1.85% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Synchrony Financial for 30 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.

SYFVIR
Market Cap
$23.94B$1.80B
Volume
2,618,9321,782,836
Sector
FinancialsHealth
52-Week High
$88.47$11.78
52-Week Low
$63.78$5.12
Typical Hold Time
30 Days0 Days
Enterprise Value
$24.18B$1.36B
Dividend Yield
1.85%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Synchrony Financial

Synchrony Financial (SYF) trades at $73.59, down slightly by 0.04% on the day. The stock exhibits a bullish technical signal overall, with support near $73 and resistance at $75. Fundamentally, the company shows strong profitability with a 23.4% net income margin and a compelling valuation at a P/E of 7.55. Recent earnings have consistently beaten expectations, and strategic partnerships, like the one with OpenAI announced on August 17, 2026, highlight growth initiatives.

The outlook for SYF is positive, supported by robust analyst sentiment with a consensus price target of $87.50, implying significant upside. Key opportunities include high ROE and strategic expansions in digital finance. Risks involve potential consumer credit deterioration, as noted in broader market news on August 26, 2026, and increased investing cash outflows in 2026, which could pressure near-term liquidity.

Vir Biotechnology Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SYF

No sentiment data available yet.

VIR
51% Buy49% Sell
Avg holding period · 0 Days

About Synchrony Financial

Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.

Read more on SYF →

About Vir Biotechnology Inc. Common Stock

Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.

Read more on VIR →